Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab plus pembrolizumab for COVID-19 pneumonia unresponsive to standard care
2020-001160-28Phase 2Active
- Sponsor
- MEDSIR
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tocilizumab and pembrolizumab in coronavirus pneumonia and coronavirus disease 2019 (COVID-19) (2 arms), sponsored by MEDSIR. Primary endpoint: Percentage of patients with normalization of SpO2 >=96% through day 14 after study treatment initiation. Started Apr 2020; status: active.
02
Drugs
tocilizumabpembrolizumab
03
Conditions
coronavirus pneumoniacoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001160-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001160-28.